ArticleUnited European gastroenterology journal2022
PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.
Article in United European gastroenterology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.United European gastroenterology journal · 2024Pooled it
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Sampling Extension, Chronic Infiltrates, and Eosinophils: Support for the Evaluation of Histological Healing in Inflammatory Bowel Disease with Endoscopic Remission.Diagnostics (Basel, Switzerland) · 2026Article
- Beyond conventional endoscopy: Image-enhanced techniques in quiescent ulcerative colitis assessment.World journal of gastrointestinal endoscopy · 2026Review
- Impact of gut microbiome on outcomes following endoscopic interventions in gastrointestinal disease.World journal of gastrointestinal endoscopy · 2025Article
- Disease Clearance in Ulcerative Colitis: A Narrative Review.United European gastroenterology journal · 2025Review
- Present and future of endoscopy precision for inflammatory bowel disease.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2024Review
- Deep mucosal healing in ulcerative colitis: how deep is better?Frontiers in medicine · 2024Review
- AI and endoscopy/histology in UC: the rise of machine.Therapeutic advances in gastroenterology · 2024Review
- Neutrophil-only Histological Assessment of Ulcerative Colitis Correlates with Endoscopic Activity and Predicts Long-term Outcomes in a Multicentre Study.Journal of Crohn's & colitis · 2023Article
- Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing.Biomedicines · 2023Review
- Current status of image-enhanced endoscopy in inflammatory bowel disease.Clinical endoscopy · 2023Review
- Real-world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey.United European gastroenterology journal · 2023Article
- Article
- Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.Frontiers in medicine · 2023Review
- New endoscopic tools in inflammatory bowel disease.United European gastroenterology journal · 2022Review
- Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?-Author's reply.United European gastroenterology journal · 2022Article
- Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?United European gastroenterology journal · 2022Article
- PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.United European gastroenterology journal · 2022Article
- Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
27 authors at 20 institutions in 8 countries.
Funding
Abstract
BACKGROUND AND
aimsA composite endoscopic-histologic remission is increasingly explored as an important endpoint in ulcerative colitis (UC). We investigated combined endoscopic-histologic remission for predicting clinical outcomes at 12 months compared with endoscopic remission alone using the high definition virtual chromoendoscopy (VCE) Paddington International virtual ChromoendoScopy ScOre (PICaSSO) and histology scores.
methodsUlcerative colitis patients, prospectively enrolled from 11 international centres, underwent VCE with targeted biopsies and followed up for 12 months. Endoscopic activity was assessed by Mayo Endoscopic Score (MES), Ulcerative Colitis Endoscopic Index Severity (UCEIS) followed by VCE-PICaSSO. Robarts Histopathological Index|Robarts Histological index≤3 without neutrophils in mucosa, and Nancy Histological index (NHI)≤ 1 were used to define histologic remission. Combined endoscopic-histologic remission was compared with endoscopic remission alone by Cox proportional hazards model and by two- and three-proportion analysis using pre-specified clinical outcomes.
results307 patients were recruited and 302 analysed. There was no difference in survival without specified clinical outcomes between PICaSSO defined endoscopic remission alone and endoscopic plus histologic remission in the rectum (HR 0.42, 95%CI 0.16-1.11 and HR 1.03, 95%CI 0.42-2.52 for Robarts Histological index and NHI respectively) at 12 months. There was however a significant survival advantage without specified clinical outcome events for UCEIS combined with histology compared with UCEIS alone (HR 0.30, 95%CI 0.12-0.75, p = 0.02) at 12 months (but not combined with NHI). For MES there was no advantage for predicting specified clinical outcomes at 12 months for endoscopy alone versus endoscopy plus histology, but there were differences in two and three proportion analysis at 6 months.
conclusionEndoscopic remission by VCE-PICaSSO alone was similar to combined endoscopic and histologic remission for predicting specified clinical outcomes at 12 months. Larger studies with specific therapeutic interventions are required to further confirm the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.